New England Journal of Medicine DECEMBER 11, 2021

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7)

Locke FL, Miklos DB, Jacobson CA, et al.

Bottom Line

The ZUMA-7 trial demonstrated that axicabtagene ciloleucel (axi-cel) significantly improves event-free survival and overall survival compared to standard-of-care high-dose chemotherapy and autologous stem-cell transplantation in patients with early relapsed or refractory large B-cell lymphoma.

Key Findings

1. Axi-cel significantly improved event-free survival (EFS) compared to standard-of-care (SOC), with a median EFS of 8.3 months versus 2.0 months (hazard ratio 0.40; P < 0.001).

2. The 24-month EFS rate was 41% for patients receiving axi-cel, compared to 16% for those receiving SOC.

3. At a median follow-up of 47.2 months, axi-cel demonstrated a significant overall survival (OS) benefit, with a hazard ratio of 0.73 (P = 0.03); the median OS was not reached in the axi-cel arm versus 31.1 months in the SOC arm.

4. The 4-year OS rate was 54.6% in the axi-cel arm compared to 46.0% in the SOC arm.

5. Axi-cel yielded higher objective response rates (83% vs 50%) and complete response rates (65% vs 32%) compared to the SOC arm.

Study Design

Design

RCT

Open-Label

Sample

359

Patients

Duration

47.2 mo

Median

Setting

Multicenter, International

Population Adults with large B-cell lymphoma who were primary refractory or relapsed within 12 months after first-line chemoimmunotherapy and were candidates for autologous stem-cell transplantation.

Intervention Axicabtagene ciloleucel (axi-cel) as a one-time infusion.

Comparator Two or three cycles of investigator-selected, protocol-defined chemoimmunotherapy, followed by high-dose chemotherapy with autologous stem-cell transplantation in patients who achieved an objective response.

Outcome Event-free survival (EFS) defined as the time from randomization to the earliest of disease progression, initiation of new lymphoma therapy, or death from any cause.

Study Limitations

• The study was open-label, which may introduce observer bias in subjective outcomes, although the primary EFS endpoint was assessed by blinded central review.

• High rates of crossover were observed in the SOC arm, as patients who did not respond to or progressed on standard treatment could receive off-protocol cellular immunotherapy, which may have confounded overall survival comparisons.

• The study required patients to be candidates for high-dose chemotherapy and stem-cell transplantation, which excludes many patients typically encountered in real-world clinical practice with significant comorbidities.

• Significant toxicities, particularly high-grade neurologic events and cytokine release syndrome, were observed in the axi-cel arm, requiring specialized management.

Clinical Significance

ZUMA-7 established axicabtagene ciloleucel as a new standard of care in the second-line setting for patients with early relapsed or refractory large B-cell lymphoma, replacing the historic paradigm of salvage chemoimmunotherapy followed by autologous stem-cell transplantation for eligible patients.

Historical Context

For over three decades, the standard curative-intent approach for patients with relapsed or refractory large B-cell lymphoma after first-line failure was intensive salvage chemoimmunotherapy followed by high-dose chemotherapy and autologous stem-cell transplantation. However, many patients were either primary refractory to initial therapy or failed to achieve a sufficient response to salvage therapy to proceed to transplant, resulting in very poor outcomes. ZUMA-7 was the first large-scale, international phase 3 trial to test CAR T-cell therapy in this earlier clinical setting.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the mechanism of action of axicabtagene ciloleucel, and why does this 'living drug' represent a departure from traditional cytotoxic chemotherapy in treating large B-cell lymphoma?

Key Response

Axicabtagene ciloleucel (axi-cel) is an autologous CAR-T cell therapy where a patient's T cells are genetically engineered to express a Chimeric Antigen Receptor (CAR) targeting CD19 on B cells. Unlike chemotherapy, which relies on interfering with DNA replication or cellular division, CAR-T cells provide a targeted, immune-mediated attack that can persist and expand in vivo, overcoming the chemoresistance often seen in early-relapsing lymphoma.

Resident

In the management of a patient with Large B-Cell Lymphoma (LBCL) who relapses 6 months after finishing R-CHOP, how does the ZUMA-7 data change the traditional 'salvage chemotherapy followed by ASCT' paradigm?

Key Response

Traditionally, patients with relapsed LBCL were treated with platinum-based salvage chemotherapy, and only those with chemo-sensitive disease proceeded to autologous stem-cell transplantation (ASCT). ZUMA-7 showed that for 'early relapsers' (relapse <12 months), axi-cel significantly outperformed this standard, leading to a median event-free survival of 8.3 months vs 2.0 months, establishing CAR-T as the preferred second-line therapy for this specific high-risk subgroup.

Fellow

Discuss the clinical significance of the Overall Survival (OS) benefit observed in ZUMA-7 despite the high rate of crossover to third-line CAR-T therapy in the standard-of-care arm.

Key Response

ZUMA-7 demonstrated a statistically significant improvement in OS (HR 0.73) for axi-cel over standard-of-care. This is particularly notable because 57% of patients in the standard-of-care arm eventually received CAR-T therapy as a subsequent treatment. The fact that an OS benefit was still reached suggests that moving CAR-T to the second-line setting is superior to reserving it for the third-line, likely due to disease progression or clinical decline preventing later-line eligibility.

Attending

Given the ZUMA-7 results, how should we approach the 'platinum-sensitive' requirement historically used to gatekeep curative-intent second-line therapy?

Key Response

ZUMA-7 challenges the requirement for platinum sensitivity as a prerequisite for curative therapy. In the standard-of-care arm, many patients failed to even reach ASCT because they did not respond to salvage chemotherapy. By bypassing the need for a chemo-response gatekeeper, axi-cel allows a higher percentage of patients (94% in the axi-cel arm vs 36% in the SOC arm) to actually receive the intended definitive therapy, fundamentally shifting the treatment philosophy for early-relapse LBCL.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Analyze the impact of 'manufacturing failure' and the intention-to-treat (ITT) principle on the internal validity of the ZUMA-7 trial compared to the per-protocol analysis.

Key Response

In cell therapy trials, the ITT population includes patients who were randomized but may not have received the product due to manufacturing failures or rapid progression. In ZUMA-7, the ITT analysis remained robust, but researchers must account for the fact that 'treatment assigned' is not 'treatment received.' The high success rate of axi-cel manufacturing (low failure rate) compared to other CAR-T products is a critical variable when translating these trial results into real-world effectiveness and health-economic models.

Journal Editor

How does the inclusion of 'initiation of new lymphoma therapy' as an event in the Event-Free Survival (EFS) endpoint potentially bias the comparison between the axi-cel and standard-of-care arms?

Key Response

EFS was the primary endpoint, defined as death, progression, or the start of a new therapy. In the standard-of-care arm, clinicians might be quicker to start 'new therapy' if a patient shows a suboptimal response to salvage chemo, whereas the axi-cel arm has a built-in waiting period for manufacturing. A critical reviewer must assess if this endpoint artificially penalizes the standard-of-care arm or if it accurately reflects the clinical reality of treatment failure and the necessity of pivoting to alternative strategies.

Guideline Committee

Based on ZUMA-7 and the TRANSFORM trial, what specific updates should be made to the NCCN guidelines regarding the treatment of patients with LBCL relapsing >12 months after primary therapy?

Key Response

Current NCCN guidelines (version 1.2023+) have been updated to recommend CAR-T (axi-cel or liso-cel) as Category 1, preferred second-line therapy for patients with primary refractory or early relapsed (<12 months) LBCL. However, for 'late relapsers' (>12 months), the evidence is less definitive, as ZUMA-7 specifically enrolled early relapsers. Therefore, guidelines should maintain salvage chemotherapy and ASCT as a standard option for late relapsers until dedicated prospective data for that subgroup emerges.

Clinical Landscape

Noteworthy Related Trials

2017

ZUMA-1 Trial

n = 101 · NEJM

Tested

Axicabtagene ciloleucel

Population

Patients with refractory aggressive B-cell non-Hodgkin lymphoma

Comparator

None (single arm)

Endpoint

Objective response rate

Key result: The study demonstrated significant clinical activity of axi-cel in patients with refractory large B-cell lymphoma, leading to its initial FDA approval.

2022

TRANSFORM Trial

n = 184 · NEJM

Tested

Lisocabtagene maraleucel

Population

Patients with primary refractory or relapsed large B-cell lymphoma

Comparator

Standard of care (salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation)

Endpoint

Event-free survival

Key result: Lisocabtagene maraleucel significantly improved event-free survival compared to standard of care in the second-line treatment of LBCL.

2022

BELINDA Trial

n = 322 · NEJM

Tested

Tisagenlecleucel

Population

Patients with aggressive B-cell non-Hodgkin lymphoma who were refractory or relapsed within 12 months

Comparator

Standard of care (salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation)

Endpoint

Event-free survival

Key result: Tisagenlecleucel did not show a benefit in event-free survival compared to standard of care salvage therapy.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis